The biomarker study will involve 4,000 patients with Parkinson’s, Alzheimer’s and other diseases of brain aging, and 1,000 healthy, age-matched controls. The study will run at the UC Gardner Neuroscience Institute but plans to be inclusive and representative of the Cincinnati population. The study protocol evolved from discussions within the Executive Committee of the Parkinson Study Group, the largest not-for-profit scientific network of Parkinson centers in North America.
“My father wanted to eradicate this disease for my mother,” said Peggy Johns, daughter of James and Joan Gardner. “We hope that findings from this study will shed light on the many causes of neurodegenerative diseases and bring us light-years forward in finding a cure or cures.”
“With the help of the Gardner family, the UC Gardner Neuroscience Institute is setting the standard for neurologic research, treatment and education,” said UC President Neville Pinto. “Their pioneering support has helped make Cincinnati the destination for patients seeking next-level neurologic care, and we are forever grateful for them.”
In a given year, about 60,000 Americans will be diagnosed with Parkinson’s disease, a progressive neurodegenerative disorder that affects movement. An estimated 5.8 million Americans are living with Alzheimer’s, a type of dementia that causes problems with memory, thinking and behavior.